Sign In
Buy PHRRF
$0.0470
+0.0004 (+0.772%)
At Close: Jun 03, 2026
PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines
08:00am, Wednesday, 27'th May 2026
MEDBOTX™ represents the evolution into a broader point-of-care manufacturing platform designed for personalized medicines, peptides and advanced dose formats Potential U.S. peptide reclassification
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
10:11am, Wednesday, 13'th May 2026
Independent research identified cepharanthine as a potential Hantavirus entry inhibitor, supporting further evaluation of Sairiyo's patented, orally bioavailable PD-001 cepharanthine formulation for H
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
08:50am, Wednesday, 13'th May 2026
Independent research identified cepharanthine as a potential Hantavirus entry inhibitor, supporting evaluation of Sairiyo's patented, orally bioavailable PD-001 formulation of cepharanthine for Hantav
Company believes supportive U.S. policy momentum may strengthen the strategic value of its ketamine patch, KetaVault™ platform, retained ketamine programs, and prior FDA-approved ketamine ANDA trans
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
08:00am, Monday, 20'th Apr 2026
U.S. regulatory momentum in psychedelics and peptides could open new commercial opportunities for PharmaTher's PatchPrint™ automated manufacturing platform and PharmaPatch™ product platform as an
Anticipated peptide reclassification could expand the addressable market for PharmaTher's PharmaPatch™ product strategy and PatchPrint™ manufacturing platform, strengthening its position in next-g
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
08:00am, Monday, 13'th Apr 2026
Patent filing intended to strengthen PharmaTher's peptide formulation capabilities for PharmaPatch™ while complementing PatchPrint™ as part of the Company's broader microneedle patch development a
PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
08:00am, Thursday, 26'th Mar 2026
Leveraging its PharmaPatch™ experience, the Company is introducing PatchPrint™ to support existing microneedle patch programs and expand into on-demand personalized patch solutions, including pept
PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market
08:00am, Tuesday, 03'rd Mar 2026
Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company, today announced a new s
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
08:00am, Wednesday, 14'th Jan 2026
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking t
PharmaTher CEO Publishes Letter to Shareholders
08:00am, Friday, 02'nd Jan 2026
Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a le
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
09:53am, Tuesday, 02'nd Dec 2025
Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the
Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking t
Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the
